Cargando…
New Progress of Epigenetic Biomarkers in Urological Cancer
Urological cancers consist of bladder, kidney, prostate, and testis cancers and they are generally silenced at their early stage, which leads to the loss of the best opportunity for early diagnosis and treatment. Desired biomarkers are scarce for urological cancers and current biomarkers are lack of...
Autores principales: | Wu, Peng, Cao, Ziyi, Wu, Song |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993951/ https://www.ncbi.nlm.nih.gov/pubmed/27594736 http://dx.doi.org/10.1155/2016/9864047 |
Ejemplares similares
-
Epigenetics of Urological Cancers
por: Schulz, Wolfgang A., et al.
Publicado: (2019) -
Epigenetic therapy in urologic cancers: an update on clinical trials
por: Faleiro, Inês, et al.
Publicado: (2016) -
Targeting the Immune system and Epigenetic Landscape of Urological Tumors
por: Lobo, João, et al.
Publicado: (2020) -
Modern urology perspectives on prostate cancer biomarkers
por: Szeliski, Kamil, et al.
Publicado: (2018) -
Emerging photodynamic/sonodynamic therapies for urological cancers: progress and challenges
por: Hu, Xiao, et al.
Publicado: (2022)